Treatment of sporadic inclusion body myositis with bimagrumab

Neurology

Volumn 83, Issue 24, 2014, Pages 2239-2246

  Amato, Anthony A ^a   Sivakumar, Kumaraswamy ^d   Goyal, Namita ^e   David, William S ^e   Salajegheh, Mohammad ^a   Praestgaard, Jens ^g   Lach Trifilieff, Estelle ^f,g   Trendelenburg, Anne Ulrike ^f,g   Laurent, Didier ^f,g   Glass, David J ^f,g   Roubenoff, Ronenn ^f,g   Tseng, Brian S ^f,g   Greenberg, Steven A ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; ACTIVIN RECEPTOR 2 A; ACTIVIN RECEPTOR 2 B; BIMAGRUMAB; PLACEBO; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 2; BLOCKING ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN;

ACNE; ADULT; AGED; ARTHRALGIA; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HERPES ZOSTER; HUMAN; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; LEAN BODY WEIGHT; MALE; MOLECULAR PATHOLOGY; MULTICENTER STUDY; MUSCLE BIOPSY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE SPASM; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROMUSCULAR DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN ABSCESS; SPORADIC INCLUSION BODY MYOSITIS; STREPTOCOCCAL PHARYNGITIS; TRANSLATIONAL RESEARCH; URINARY TRACT INFECTION; WALKING; WESTERN BLOTTING; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; EXERCISE TEST; METABOLISM; MIDDLE AGED; MYOSITIS, INCLUSION BODY; NEUROMUSCULAR DISEASES; ORGAN SIZE; PATHOLOGY; PHOSPHORYLATION; SKELETAL MUSCLE; THIGH; TREATMENT OUTCOME; VERY ELDERLY;

ACTIVIN RECEPTORS, TYPE II; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; EXERCISE TEST; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; NEUROMUSCULAR DISEASES; ORGAN SIZE; PHOSPHORYLATION; SMAD2 PROTEIN; SMAD3 PROTEIN; THIGH; TREATMENT OUTCOME;

EID: 84924156115     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.0000000000001070     Document Type: Article

References (24)

1. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-631.
2. Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol 2012;25:630-639.
3. Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 59-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-418.
4. Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 59-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407.
5. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012;11:790-811.
6. Sako D, Grinberg AV, Liu J, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem 2010;285:21037-21048.
7. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: An overview. J Cachexia Sarcopenia Muscle 2011;2:143-151.
8. Sartori R, Milan G, Patron M, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009;296:C1248-C1257.
9. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009;296:C1258-C1270.
10. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014-1019.
11. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology 2000;55:1385- 1387.
12. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: development and validation. Epidemiology 1990;1:58-64.
13. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002;58: 1081-1087.
14. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999;286:1738-1741.
15. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3) K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001;3:1009-1013.
16. Lai KM, Gonzalez M, Poueymirou WT, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004;24:9295-9304.
17. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 1997;48:712-716.
18. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 2000;247:22-28.
19. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327.
20. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566-1570.
21. Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-372.
22. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718-720.
23. Schroeder ET, He J, Yarasheski KE, et al. Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation. Eur J Appl Physiol 2012;112:1123-1131.
24. Frontera WR, Hughes VA, Krivickas LS, Kim SK, Foldvari M, Roubenoff R. Strength training in older women: early and late changes in whole muscle and single cells. Muscle Nerve 2003;28:601-608.